论文部分内容阅读
Metastasis is the primary cause of cancer related mortality.Immunotherapy is becoming the most promising new modality for cancer treatment, which can lead to complete and long-lasting treatment response, central for preventing cancer metastasis and disease relapse.Clinical trials with monoclonal antibodies to immune checkpoint inhibitory receptor PD-1 and its ligand PD-L1 have shown remarkable clinical response in melanoma, renal carcinoma and non-small-cell lung cancer patients with unprecedented survival benefit.